Drug intelligence / Profile preview

GQ-501

Development stage: Preclinical
Lead developer: Pacira BioSciences
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intraarticular

Overview

GQ-501 is a gene therapy drug candidate developed for the treatment of osteoarthritis. It is a helper-dependent adenoviral vector that expresses two therapeutic proteins: proteoglycan 4 (also known as lubricin) and interleukin-1 receptor antagonist (IL-1Ra). The mechanism of action involves stimulating IL-1Ra, which inhibits inflammatory signaling mediated by interleukin 1, and modulating PRG4/lubricin, which plays a role in joint lubrication and cartilage protection. The drug is being developed by GQ Bio Therapeutics GmbH (formerly GeneQuine Biotherapeutics GmbH), with its highest development phase reported as preclinical[1][2].

Targets

IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on GQ-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GQ-501.

Explore the full profile